Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
Key claim: A phase II trial is evaluating whether administering ruxolitinib before, during, and after allogeneic HSCT reduces GVHD incidence and severity while improving survival and quality of life in primary and secondary myelofibrosis patients.
Abstract
This phase II trial studies how well administering ruxolitinib before, during, and after allogeneic hematopoietic stem cell transplantation works in preventing graft versus host disease and improving transplant outcomes in patients with primary and secondary myelofibrosis. Donor hematopoietic stem cell transplantation (HSCT) is currently the only treatment with proven curative potential for myelofibrosis, however, myelofibrosis patients have a high risk for developing graft versus host disease post-transplant. Graft versus host disease is a condition where the transplanted cells from a donor can attack the body’s normal cells. Ruxolitinib, a janus-associated kinase (JAK) inhibitor, is known to decrease inflammatory signals, which may reduce spleen size and decrease symptoms such as night sweats and weight loss. Administering ruxolitinib before, during, and after transplant may decrease the incidence and severity of graft versus host disease, increase survival, and improve quality of life in patients with primary and secondary myelofibrosis.
Why this matters
Ruxolitinib’s role in MPN transplant decision-making is expanding from a pre-transplant cytoreductive bridge to a continuous peritransplant agent that may also suppress GVHD. A structured phase II protocol covering pre-, peri-, and post-HSCT dosing in both primary and secondary myelofibrosis would clarify whether the GVHD and survival signals seen in earlier reports hold up prospectively, and could reshape conditioning and prophylaxis standards for MF allo-HSCT.